Inovio Pharmaceuticals Inc vs Trip.com Group Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Trip.com Group Ltd trades at $43.78 (market cap $28.12B). The key difference: Trip.com Group Ltd is far larger — about 315× Inovio Pharmaceuticals Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TCOM | |
|---|---|---|
Market Cap | $89.27M | $28.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $78.96 |
52-Week Low | $1.05 | $39.84 |
Enterprise Value | $60.28M | $20.82B |
Dividend Yield | — | 0.42% |
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →